Anti-inflammatory Drugs Market

Anti-inflammatory Drugs Market Size

Anti-inflammatory Drugs Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 111.4 billion and is projected to reach USD 264.3 billion by the completion of 2034.

Anti-inflammatory drugs reduce inflammation, which is the body's response to injury or infection. They stop the body from producing certain chemicals like prostaglandins which cause inflammation and pain. Anti-inflammatory drugs are often classified into different groups such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin, which block inflammation-related enzymes; and corticosteroids, which reduce inflammation by the suppression of the immune system. These medications are frequently used for the treatment of ailments such as arthritis, muscle discomfort, and various inflammatory diseases. Besides, while these drugs are effective, they can have adverse effects such as gastrointestinal difficulties and a high risk of cardiovascular disease if used for an extended period.

Market Highlights

Anti-inflammatory Drugs Market is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2034

Anti-inflammatory drugs market is projected to reach USD 264.3 billion over the forecast period, owing to a rise in chronic inflammatory conditions, like arthritis and autoimmune diseases. The market for anti-inflammatory drugs includes a variety of products, which range from prescription to over-the-counter medications. Innovation in drug formulations and targeted therapy is boosting the growth of the market by improving efficacy and lowering side effects. In addition, biologics and next-generation NSAIDs are becoming highly popular due to their effectiveness and safety characteristics. Moreover, pharmaceutical companies and new biotech firms are engaged in competitive dynamics as they continue to conduct research to find modern treatments. Besides, the industry is experiencing high activity in strategic partnerships and acquisitions, which are expanding the range of therapies.

Source: Fatpos Global

Anti-inflammatory Drugs Market Segmentation

Nonsteroidal Anti-inflammatory Drugs segment will lead the industry due to its prolonged usage and efficiency

Anti-inflammatory Drugs Market is divided by Drug Type into Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics, and Corticosteroids. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are the leading segment in the market due to their large usage and proven effectiveness. NSAIDs like ibuprofen and aspirin are used for various conditions such as acute pain and chronic inflammatory illnesses. Their easy accessibility and relatively lower cost contribute to their popularity. They operate by blocking enzymes that are engaged in inflammation and provide relief from pain as well as swelling. In addition, NSAIDs can be purchased without a prescription, which further extends their availability in the market. Although they may cause some side effects, their reliability and long history make them dominant in the market for anti-inflammatory medications.

Oral segment will lead the market due to its ease of use and popularity

Anti-inflammatory Drugs Market is segmented by Route of Administration into Oral, Topical, Injection, and Inhalation. The oral segment is the dominant category in the anti-inflammatory drugs market owing to its convenience and popularity. Oral medications such as tablets and capsules are popular due to their administration and affordability. They are frequently recommended for treating long-term illnesses such as arthritis and can be purchased without a prescription or with one. Moreover, the vast access and proven effectiveness of oral anti-inflammatory medications add to their popularity. Even though topical, injection, and inhalation methods have their benefits for specific treatments, the oral route is still the most readily available and commonly used option for controlling inflammation.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Rising Prevalence of Chronic Inflammatory Diseases is Driving Growth in the Anti-inflammatory Drugs Market

High prevalence of chronic inflammatory diseases like osteoarthritis, inflammatory bowel disease, and rheumatoid arthritis has a significant effect on the need for anti-inflammatory drugs. The age of population and lifestyle is constantly changing due to which there is a need for efficient therapies to keep up with the high number of prevalent ailments. Chronic illnesses require regular care, which leads to prolonged use of anti-inflammatory drugs. This trend is further supported by innovations in diagnostics, which allow for the more accurate detection of disorders. Therefore, as more people are diagnosed and seek treatment, the anti-inflammatory medicine market is expected to grow to meet the needs of the general public.

Advancements in Drug Development Act as a Catalyst for Market Growth

Improvements in drug development play an important role in propelling growth in the anti-inflammatory drugs market. The emergence of new types of medications, like biologics and NSAIDs, provides fewer side effects in comparison to traditional therapies. Biologics are designed to focus on specific inflammatory pathways and offer personalized treatment choices for severe situations. In addition, ongoing research and development efforts to generate advanced anti-inflammatory drugs with better safety are further propelling market growth by attracting patients and medical professionals who are seeking new treatment options.

Restraints

Side Effects and Safety Concerns in the Market Will Impact the Growth

Even though anti-inflammatory drugs are effective, they still have significant side effects that may limit their usage. Prolonged use of NSAIDs can lead to gastrointestinal problems such as ulcers and bleeding, whereas corticosteroids may lead to weight gain and higher chances of infections. Thus, healthcare providers must carefully assess the risks and benefits for each patient, which results in potential limitations on the use of these drugs. Moreover, concerns regarding the cardiovascular dangers of prolonged NSAID use also limit their usage.

Recent Developments

• In June 2024, Pfizer announced positive results from a Phase 3 clinical trial for its new anti-inflammatory drug targeting rheumatoid arthritis, showing significant improvement in patient outcomes.
• In April 2024, Johnson & Johnson received FDA approval for its new topical anti-inflammatory cream designed to treat chronic eczema, offering a novel treatment option for patients.
• In February 2024, Novartis launched a new biologic drug for the treatment of psoriatic arthritis, which demonstrated high efficacy in reducing joint inflammation and skin symptoms in clinical trials.
• In July 2024, GlaxoSmithKline announced the successful completion of its Phase 2 trials for a new anti-inflammatory inhaler aimed at managing severe asthma, showing promising results in reducing flare-ups.
• In March 2024, AbbVie introduced a new oral anti-inflammatory medication for inflammatory bowel disease, which received fast-track designation from the FDA due to its potential to improve patient quality of life significantly.

Anti-inflammatory Drugs Market

Key Players:

• Pfizer Inc.
• Johnson & Johnson
• Novartis International AG
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AbbVie Inc.
• Amgen Inc.
• Sanofi S.A.
• Roche Holding AG
• Eli Lilly and Company
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Anti-inflammatory Drugs Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region is leading the anti-inflammatory drugs market due to its advanced healthcare system and dedicated research and development efforts. The pharmaceutical sector of the North American region fuels creativity and offers vast availability of new treatments. Furthermore, the occurrence of chronic inflammatory diseases and a solid healthcare infrastructure play a major role in the dominance of North America in the anti-inflammatory drugs market.

Europe is projected to experience remarkable growth in the next ten years as a result of higher investment in healthcare innovation, which increases the need for modern treatments. In addition, a supportive regulatory structure and many partnerships between pharmaceutical companies and research institutions are beneficial for the European market.

Source: Fatpos Global

Impact of COVID-19 on the Anti-inflammatory Drugs Market

Anti-inflammatory drugs market was greatly affected by the COVID-19 pandemic in various ways. At first, there was an increase in the need for anti-inflammatory medicines due to the impact of COVID-19, which resulted in higher sales of medications such as corticosteroids. However, the global supply chains were majorly interrupted by the pandemic, thereby causing an impact on the production of drugs. Furthermore, healthcare systems became overburdened, which led to a decline in normal treatments and affected the ability of patients to receive anti-inflammatory therapies. Despite these difficulties, the pandemic boosted the implementation of digital health solutions and provided new opportunities for drug delivery and patient care.

Anti-inflammatory Drugs Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and the Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Anti-inflammatory Drugs Market Scope and Segments: